Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;10(5):444-456.
doi: 10.1016/j.trecan.2024.01.008. Epub 2024 Feb 14.

Immunotherapy for colorectal cancer: insight from inherited genetics

Nijole Pollock Tjader  1 , Amanda Ewart Toland  2
Affiliations
Review

Immunotherapy for colorectal cancer: insight from inherited genetics

Nijole Pollock Tjader et al. Trends Cancer. 2024 May.

Abstract

Immunotherapy shows efficacy for multiple cancer types and potential for expanded use. However, current immune checkpoint inhibitors (ICIs) are ineffective against microsatellite-stable colorectal cancer (CRC), which is more commonly diagnosed. Immunotherapy strategies for non-responsive CRC, including new targets and new combination therapies, are being tested to address this need. Importantly, a subset of inherited germline genetic variants associated with CRC risk are predicted to regulate genes with immune functions, including genes related to existing ICIs, as well as new potential targets in the major histocompatibility complex (MHC) region and immunoregulatory cytokines. We review discoveries in the inherited genetics of CRC related to the immune system and draw connections with ongoing developments and emerging immunotherapy targets.

Keywords: GWAS; colorectal cancer; immune checkpoint inhibitor; immunotherapy; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1, Key Figure:
Figure 1, Key Figure:. Variants in immune-related genes associated with CRC.
Variants (indicated by rsIDs) associated with CRC risk or survival from GWAS and/or candidate gene studies and their corresponding immune gene-encoding proteins and main cell types are shown. Cell types include tumor cells (yellow), APCs (blue, branching), macrophages (pink), NK and effector T cells (purple), neutrophils (gray), MDSCs (green), and Th17 cells (blue, round), while interactions involve cytokines (circles), receptors (chevrons) and cell surface proteins (triangles). (i) Variants on the left (yellow background) are genes associated with pro-inflammatory cytokines (IL-33, IL-1α, IL-1β, CXCR1, CXCR2, IL-6, IL-17F, IL-17A) downstream effectors of inflammation (TOX, SH2B3), or pro-tumorigenic interactions between tumor and NK and T cells (CTLA4, PD-1, PD-L1, HLA-G, KIR2DS5 and KIR2DS3) (ii) Genes associated with anti-tumor effectors are listed on the right (green background). Abbreviations: CRC, colorectal cancer; GWAS, Genome-wide association study; APCs, antigen presenting cells; NK, Natural Killer; MDSC, myeloid-derived suppressor cell; Th17, T-helper 17. *genes with mixed or uncertain effects
See this image and copyright information in PMC

References

    1. Lei Q et al. (2020) Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Front. cell Dev. Biol 8, 672. - PMC - PubMed
    1. Zou C et al. (2018) CTLA4 tagging polymorphisms and risk of colorectal cancer: a case-control study involving 2,306 subjects. Onco. Targets. Ther 11, 4609–4619 - PMC - PubMed
    1. Chalabi M et al. (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med 26, 566–576 - PubMed
    1. Overman MJ et al. (2018) Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J. Clin. Oncol 36, 773–779 - PubMed
    1. Gutierrez C et al. (2023) The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States. JCO Precis. Oncol 7, e2200179. - PMC - PubMed

Publication types

MeSH terms